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Abstract
Background Drug-induced photosensitivity refers to the development of cutaneous adverse events due to interaction
between a pharmaceutical compound and sunlight. Although photosensitivity is a very commonly listed side-effect of
systemic drugs, reliable data on its actual incidence are lacking so far.
Objectives A possible approach to evaluate the real-life extent of drug-induced photosensitivity would be an analysis
of the frequency of exposure to a given photosensitizing drug combined with an indicator of its photosensitizing poten-
tial. This could serve as a basis for developing a pharmaceutical ‘heatmap’ of photosensitivity.
Methods The present study investigated the number of reimbursed dispensed packages of potentially photosensitizing
drugs in Germany (DE) and Austria (AT) between 2010 and 2017 based on nationwide health insurance-based data-
bases. In addition, an indicator for the photosensitizing potential was established for each drug based on the number of
reports on photosensitivity in the literature.
Results This analysis includes means of 632 826 944 (+/14 894 918) drug dispensings per year in DE and 113 270
754 (+/1 964 690) in AT. Out of these, the mean percentage of drugs that enlist photosensitivity as a potential
side-effect was 49.5% (0.7) in DE and 48.2% (1.2) in AT. When plotting the number of reimbursed dispensed
packages vs. the number of reports on photosensitivity, two categories of drugs show high numbers for both parame-
ters, that is diuretics and non-steroidal anti-inflammatory drugs (NSAIDs).
Conclusions Diuretics and NSAIDs appear to be responsible for the greatest part of exposure to photosensitizing
drugs with potential implication on public health.
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Drug-induced photosensitivity refers to the development of
cutaneous adverse events due to interaction between a given
pharmaceutical compound and sunlight. Photosensitizing drugs
act as exogenous chromophores that are transformed by
absorption of photons into a photochemically active excited
state and subsequently undergo chemical reactions.1 Manifesta-
tions of drug-induced photosensitivity can be subdivided into
phototoxic and photoallergic reactions. The action spectrum
mostly lies within the UVA range although some drugs are acti-
vated by visible light or UVB radiation or a combination of
different wavelengths.2 The mechanisms for tissue damage in
phototoxicity involve oxidation of cellular lipids, proteins and
DNA, often mediated by reactive oxygen species (ROS),3,4 or
formation of stable photoadducts.5 Photoallergy represents a T-
cell-mediated delayed-type hypersensitivity reaction that
involves covalent binding of a pharmaceutical compound to an
endogenous protein in the presence of solar radiation.2 The
great majority of reactions to systemic drugs are phototoxic in
nature, whereas topical agents such as chemical UV filters or
non-steroidal antirheumatics are the main causes of photoaller-
gic reactions.6,7
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Up to the present, a vast number of drugs have been associ-
ated with photosensitivity and the number is increasing every
year.8 In particular, antimicrobials, non-steroidal anti-inflam-
matory drugs (NSAIDs), cardiovascular agents and psychotrop-
ics have been implicated in photosensitive reactions.1 In general,
the elderly population is at higher risk given its greater con-
sumption of different drugs for the treatment of chronic dis-
eases.9 Besides acute cutaneous adverse effects, an increasing
number of reports also suggest chronic sequelae such as
increased photoaging or photocarcinogenesis.8,10 However, as
yet this is still a matter of controversial scientific discussions.
Although drug-induced photosensitivity is considered to
account for up to 8% of reported cutaneous adverse events from
drugs,1,11 reliable data on its actual incidence are lacking so far.
It is generally assumed that drug-induced photosensitivity is
heavily underreported owing to a lack of clinical recognition and
a lack of reporting to databases.2 This most probably results in
an appreciable number of underdiagnosed and underreported
cases hampering retrospective analyses of the true incidence of
drug-induced photosensitivity. A possible approach to evaluate
the actual incidence of drug-induced photosensitive reactions
would be an analysis of the ‘societal exposure’ of photosensitiz-
ing drugs combined with an indicator of their photosensitizing
potential. This could serve as a basis for delineating the photo-
sensitizing potential of currently prescribed systemic drugs.
In the present study, we investigated the number of reimbursed,
dispensed packages of photosensitizing drugs in Germany and
Austria between 2010 and 2017 based on nationwide health data-
bases on drug dispensings. These data were directly correlated with
an indicator of the photosensitizing potential of each drug. With
this approach, we aimed at identifying drugs that have both, high
dispensing rates and a high photosensitizing potential, and thus
the greatest bearing on drug-induced photosensitivity reactions.
Methods
Study design and source of data
The present work was designed as a drug utilization study target-
ing at the analysis of the dispensings of photosensitizing drugs
within defined timely and regional boundaries. The German data
set was provided by the German Institute for Drug Use Evaluation
(DAPI, Berlin, Germany) which collects anonymous claims data
of drugs prescribed and subsequently dispensed at community
pharmacies at the expense of the Statutory Health Insurance
(SHI) Funds.12 Nearly 87% of Germany’s (DE’s) population is
insured by the SHI system.13,14 The DAPI data cover 80% of the
community pharmacies in DE and were extrapolated by regional
factors to 100% of the SHI insured population. The Austrian
data set was provided by The Main Association of Austrian Social
Security Institutions which serves as the umbrella organization of
the statutory health insurances in Austria (AT). About 98% of
the Austrian population is covered by the statutory health
insurances. All costs exceeding the copayment are covered by the
health insurance.15,16 Both data sets contained longitudinal data
concerning the overall number of rates of dispensed drugs for
single (or combined) agents within a given time frame in the
respective country. Both data sets do not include drugs dis-
pensed in hospital (inpatient) settings. For additional informa-
tion, please refer to the Appendix S1 (Supporting Information).
Compilation of photosensitizing agents
To create a most complete and actual list of photosensitizing
drugs, we first referred back to the compilations published in
review articles by Moore,8 Drucker and Rosen 17 as well as Mon-
teiro et al. 1 since they seemed to provide the most complete
recent overviews on that subject. In addition, Litt’s Drug Erup-
tion & Reaction Database was consulted and further drugs (not
mentioned in the review articles) were added to the list. Drugs
listed in the database under the label ‘photosensitivity’ were
added to the list of photosensitizing drugs. Finally, a MEDLINE
search for the terms ‘photosensitivity’ as well as ‘phototoxic’/
‘photoallergic’ was performed in November 2017 in order to
complement the initial overview. For additional information,
please refer to the Appendix S1 (Supporting Information).
Development of an indicator for photosensitivity
The incidence of photosensitive adverse reactions of a given
pharmaceutical compound is the product of its prescription fre-
quency and its photosensitizing potential (though further factors
such as the UV spectrum, exposure dose, climate area or season
of exposure may also have an influence). With regard to the lat-
ter, an indicator for each drugs’ photosensitizing potential had
to be established. So far no comparative clinical or experimental
studies have been performed addressing the difference in the
photosensitizing potential across a large series of different phar-
maceutical compounds. This may be due to the many factors
influencing the clinical manifestation as well as the magnitude of
different compounds. Based on the assumption that there is a
correlation between the number of reported photosensitive side-
effects and the photosensitizing potential of a given drug, we
established the number of publications reporting a photosensi-
tive adverse drug reaction as an indicator for the photosensitiz-
ing potential of a drug. To this purpose, a MEDLINE search was
performed between April 2018 and December 2018 to systemati-
cally identify all reports for every drug mentioned in the list
above. Importantly, this analysis was only performed for drugs
that were actually prescribed in DE and/or AT within the obser-
vational period. For this analysis, the search term ‘photosensitiv-
ity’ in addition to each single drug name was used since this
would address both, reports on phototoxic and photoallergic
side-effects. Inclusion and exclusion criteria were formulated to
determine which publications qualified to be included into the
analysis. In a second step, Litt’s Drug Eruption & Reaction Data-
base was again used to complement the findings derived from
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the MEDLINE search in order to achieve a maximum number of
reports for each compound listed. The according study flow
chart is shown in Fig. 1.
Statistical analysis
The numbers of reimbursed dispensed packages were analysed
with regard to overall yearly prescriptions to assess general trends.
The agents of interest were categorized according to a classifica-
tion adapted from the World Health Organization’s Anatomical
Therapeutic Chemical (ATC) Classification System.18 Descriptive
analyses for both – drug groups and single agents – were per-
formed concerning reimbursed drug dispensings, potential of
photosensitive adverse reactions and the combination of both fea-
tures using Microsoft Excel (2016, Microsoft Corp., Redmond,
WA, USA). For details on the statistical analyses, please also refer
to the Appendix S1 (Supporting Information).
Results
Compilation of photosensitizing agents
Based on published literature and an adverse drug reaction data-
base, a compilation of photosensitizing medications has been
established (see Table 1 summarizing all drugs). In total, 387
pharmaceutical compounds could be identified that have been
associated with causing photosensitivity either from literature or
by the database. The largest group containing the highest number
of compounds was the group ‘nervous system’, while the group
‘anti-infectious’ showed the second most and the group ‘cardio-
vascular’ the third most compounds. Out of the 387 agents with
photosensitizing potential, 291 agents (75.2%) were dispensed
and reimbursed in DE and 220 (56.9%) in AT during the study
period. These drugs are highlighted in Table 1 with indications
of their use in DE (#) and/or AT (+). Therefore, Table 1 provides
both information on which drugs are more likely to cause photo-
sensitivity since they have actually been dispensed (written in
bold letters in Table 1) and information on other drugs with
photosensitizing potential (non-dispensed/reimbursed).
Frequency of photosensitizing drug dispensings
In the period between 2010 and 2017, the mean total number
of reimbursed drug packages dispensed in DE was 632.827 mio.
[14.895 mio.] per year and in AT 113.271 mio. [1.965 mio.]
per year. In DE, the total number of dispensed drug packages
rose from 617.54 mio. in 2010 to a maximum of 655.351 mio.
in 2016 and slightly decreased thereafter to 648.093 mio. in
2017 as presented in Fig. 2a. This corresponds to an increase in
drug dispensings of + 4.95% during the study period. In AT,
the total number of packages of pharmaceuticals reimbursed in
Compilation of all photosensitive agents 
based on a literature research
Analysis of total and relative dispensings of 
photosensitizing drugs in Austria and Germany
Development of an “indicator“ of the photosensitizing 
potential based on the number of publications per agent
Correlation of the dispensing rate with the 
photosensitizing potential (“indicator“)
Stratification into four major groups:
•  “X1” = agents with low number of dispensings and low number of reports on photosensitivity
•  “X2” = agents with low number of dispensings and high number of reports on photosensitivity
•  “X3” = agents with high number of dispensings and high number of reports on photosensitivity
•  “X4” = agents with high number of dispensings and low number of reports on photosensitivity
Interpretation
Figure 1 Study flow chart. First, a compilation of all photosensitive pharmaceutical agents was established based on an extensive litera-
ture research. In parallel, the total and relative number of reimbursed dispensings of photosensitizing drugs in Austria and Germany was
performed. In addition, an ‘indicator’ of the photosensitizing potential of each drug was determined based on the number of reports on
photosensitivity. Finally, the dispensing rate was graphically correlated with the ‘indicator’ resulting in four different groups of photosensi-
tizing drugs ‘X1’–‘X4’, which served as a basis for the interpretation of the results.
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Table 1 Compilation of pharmaceutical compounds with photosensitizing potential
1 Cardiovascular
Diuretics Hydrochlorothiazide #+ Bendroflumethiazide #+ Indapamide #+
Benzylhydrochlorothiazide Benzthiazide Triamterene #
Chlorothiazide Bumetanide #+ Furosemide #+
Hydroflumethiazide Butizide + Amiloride #
Methyclothiazide Cyclothiazide Torasemide #+
Piretanide # Chlorthalidone #+ Xipamide #+
Polythiazide Metolazone Ethacrynic acid
Trichlormethiazide Quinethazone Acetazolamide #+
Bemetizide # Spironolacton #+
Agents acting on the renin–angiotensin system Enalapril #+ Benazepril # Losartan #+
Ramipril #+ Lisinopril #+ Olmesartan #+
Quinapril #+ Moexipril # Telmisartan #+
Captopril #+ Valsartan #+ Irbesartan #+
Fosinopril #+ Candesartan #+
Antiarrhythmics Amiodarone #+ Disopyramide
Dronedarone #+ Procainamide
Beta blocking agents Propranolol Carvedilol #+
Sotalol #+ Tilisolol
Calcium channel blocking agents Amlodipine #+ Diltiazem #+
Nifedipine #+ Verapamil #+
Other antihypertensives Hydralazine # Methyldopa #+ Diazoxide #
Rilmenidine +
Antithrombotic agents Clopidogrel #+
Others Oxerutins # Quinidine #
2 Anti-inflammatory and antirheumatic products
Anti-inflammatory and antirheumatic products,
non-steroids (excluding Coxibs)
Naproxen #+ Benoxaprofen Benoxaprofen
Ketoprofen #+ Diflunisal Indoprofen
Tiaprofenic acid # Nabumetone # Indomethacin #+
Piroxicam #+ Benzydamine #+ Fenoprofen
Carprofen Flurbiprofen + Sulindac
Aceclofenac # Ketorolac #+ Suprofen
Diclofenac #+ Meclofenamate Ibuprofen #+
Mefenamic acid + Oxaprozin Tolmetin
Phenylbutazone #+ Meloxicam #+ Nimesulide +
Gold # Etodolac
Coxibs Celecoxib #+ Rofecoxib Valdecoxib





3 Antineoplastic and immunomodulating agents




Capecitabine #+ Tegafur/Uracil # Tegafur/Gimeracil/
Tegafur + Oteracil #
Methotrexate #+
Plant alkaloids and other natural products Vinblastine #+ Docetaxel #+ Paclitaxel #+
Anthracyclines and related substances Epirubicin #+
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Table 1 Continued
3 Antineoplastic and immunomodulating agents
Protein kinase inhibitors Vemurafenib #+ Cobimetinib #+ Dabrafenib #+
Trametinib #+ Crizotinib #+ Erlotinib #+
Regorafenib #+ Dasatinib #+ Imatinib #+
Gefitinib #+ Canertinib Alectinib +
Lapatinib #+ Vandetanib #+
Topoisomerase inhibitor Irinotecan #+
Monoclonal antibodies Nivolumab #+ Cetuximab # Trastuzumab #+
Eculizumab #+ Panitumumab #+
Others Hydroxyurea # Flutamide #+ Rucaparib
Procarbazine # Bicalutamide #+ Anagrelide #
PEG interferon #+ Midostaurin + Arsenic #
Interferon alpha #+
4 Anti-infectives
Fluoroquinolones Lomefloxacin #+ Ulifloxacin + Ofloxacin #+
Fleroxacin Ciprofloxacin #+ Trovafloxacin
Clinafloxacin Grepafloxacin Gatifloxacin
Sparfloxacin Gemifloxacin Moxifloxacin #+
Enoxacin # Levofloxacin #+ Norfloxacin #+
Pefloxacin
Tetracyclines Tetracycline #+ Doxycycline #+ Chlortetracycline #
Oxytetracycline # Minocycline #+ Lymecycline +
Demeclocycline #
Sulfonamides Sulphamethoxazole Sulphadiazine #+
Cotrimoxazol #+ Sulphisoxazole
Cephalosporins Cefazolin #+ Ceftazidime #+ Cefotaxime #+
Aminoglycosides Kanamycin # Streptomycin # Gentamicin #+
Antimycotics Griseofulvin # Terbinafine #+ Itraconazole #+
Voriconazole #+ Ketoconazole #+ Rosemary #
Antimycobacterials Isoniazid #+ Ethionamide Clofazimine
Pyrazinamide #+ Ethambutol #+ Aminosalicylate
sodium #+
Antivirals Efavirenz #+ Daclatasvir #+ Acyclovir /
Valaciclovir #+
Ritonavir #+ Amantadine #+ Simeprevir #+
Saquinavir #+ Ganciclovir/ Ribavirin #+
Zalcitabine Valganciclovir #+
Others Quinine # Mefloquine #+ Dapsone #
Chloroquine # Pyrimethamine # Furazolidone
Hydroxychloroquine # Quinacrine Methenamine #
Azithromycin #+ Sulphadoxine Flucytosine #
5 Nervous system
Antidepressants Protriptyline Escitalopram #+ Duloxetine #+
Amitriptyline #+ Paroxetine #+ Isocarboxazid
Imipramine # Hypericum #+ Phenelzine
Clomipramine #+ Fluvoxamine #+ Tranylcypromine #+
Desipramine # Fluoxetine #+ Amoxapine
Trimipramine # Sertraline #+ Trazodone #+
Nortriptyline # Citalopram #+ Nefazodone
Doxepin #+ Venlafaxine #+
Bupropion #+
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Table 1 Continued
5 Nervous system
Antipsychotics Chlorpromazine Olanzapine #+ Chlorprothixene #+
Thioridazine # Clozapine #+ Perazin #
Fluphenazine # Haloperidol #+ Loxapine #
Perphenazine #+ Mesoridazine
Flupentixol #+ Trimeprazine Quetiapine #+
Molindone Prochlorperazine Risperidone #+
Pimozide #+ Trifluoperazine Maprotiline #+
Thiothixene Ziprasidone #+
Anxiolytics Meprobamate + Alprazolam #+
Clorazepate # Chlordiazepoxide #
Hypnotics and sedatives Zolpidem #+ Triazolam #+ Promethazine #
Eszopiclone Butobarbital Pentobarbital
Zaleplon #
Anticonvulsants/Barbiturates Carbamazepine #+ Topiramate #+ Butabarbital
Lamotrigine #+ Valproic acid #+ Butalbital
Phenytoin #+ Trimethadione Pentobarbital
Felbamate #+ Phenobarbital #
Selective serotonin (5HT1) agonists Sumatriptan #+ Zolmitriptan #+ Almotriptan #
Naratriptan #+
Others Acamprosate #+ Carisoprodol Procyclidine #+
Methylphenidate #+ Cevimeline # Trihexyphenidyl #
Ropinirole #+
6 Metabolism/endocrine therapy
HMG-CoA reductase inhibitors Simvastatin #+ Pravastatin #+ Rosuvastatin #+
Atorvastatin #+ Pitavastatin #
Fibrates Clofibrate Bezafibrate #+ Fenofibrate #+




Glipizide + Acetohexamide Metformin #+
Tolbutamide Glimepiride #+ Tolazamide
Proton-pump inhibitors Esomeprazole #+ Pantoprazole #+ Rabeprazole #+
Antigout preparations Allopurinol #+ Febuxostat #+ Colchicine #+
Hormones Melatonin #+ Oestrogen #+ Progesterone #+
Hydrocortisone #+ Epoetin alpha # Ethinyl estradiol #+
Danazol +
Antihistamines Mequitazine # Clemastine # Dimenhydrinate #
Repirinast Dexchlorpheniramine # Cyproheptadine #+
Astemizole Hydroxyzine #+ Diphenhydramine #+
Azatadine Meclizine Loratadine #+
Brompheniramine Tripelennamine # Cetirizine #+
Chlorpheniramine # Triprolidine
Ranitidine #+ Terfenadine #




Anticholinergic Scopolamine # Benzatropine Atropin sulphate #
Hyoscyamine # Glycopyrrolate #+ Tiotropium #+
Cholinergic Pilocarpine #+
PDE5 inhibitors Sildenafil #+ Vardenafil #+
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the outpatient sector remained relatively stable over the years
[increasing from 112.931 mio. in 2010 to a maximum of
115.761 mio. in 2014 and decreasing to 109.073 mio. in 2017
(see Fig. 2b)]. When relating these numbers to the amount of
the total number of insured persons per year, a similar picture
evolves (Fig. 3c,d).
Out of these total drug dispensings, the mean percentage of
photosensitizing agents was 49.5% (0.7) in DE and 48.2%
(1.2) in AT over the entire study period. The overall use of pho-
tosensitizing drugs rose from 309.416 mio. in 2010 to 313.161
mio. in 2017 in DE, representing an increase of 3.745 mio, includ-
ing a peak of 320.021 mio. in 2016 (see Fig. 2e,g,i). In AT, the
overall number of photosensitizing drug dispensings was
51 600 780 in 2010 that rose to 57 426 060 in 2014 and decreased
to 52 176 413 in 2017 (see Fig. 2f,h,j). These findings reveal that
the absolute dispensing rates of photosensitizing drugs were
increasing during the initial phase of the observational period in
both countries. However, in both countries a decrease in total
photosensitizing drug dispensings was observed over the last years
(which was much more profound in AT). Interestingly, the rela-
tive amount of photosensitizing drug prescriptions (in %) showed
a continuous decrease in DE over years, while the number in AT
only decreased during the last 3 years (Fig. 3g,h).
Distribution of photosensitizing agents and number of
dispensings across drug classes
Photosensitizing drugs differ across drug classes both with
respect to the total number of photosensitizing agents per
drug class and the frequency of prescriptions per year. The
category ‘nervous system’ contains the highest number of pho-
tosensitizing drugs within a category (20.7%), followed by the
categories ‘anti-infectious’ and ‘cardiovascular’ drugs (Fig. S1a,
Supporting Information). However, when looking at the mean
number of photosensitizing drug prescriptions per year in DE,
the highest dispensing numbers are found in the category ‘car-
diovascular’ (117.1 mio. dispensings, 33.0% of all dispensings)
followed by the category ‘metabolism’ (85.5 mio. dispensings,
24.1% of all dispensings; see Fig. S1b,c (Supporting Informa-
tion), number per 1000 insured persons – Fig. 1d). The
respective absolute and relative numbers in the AT population
are shown in Fig. S1e–g (Supporting Information). Interest-
ingly, the relative distribution in AT is almost identical to the
German population (also showing the highest number of dis-
pensings in the category ‘cardiovascular’, see Fig. S1g, Sup-
porting Information).
The example of the drug class ‘cardiovascular’ demonstrates
that there is often a discrepancy between the number of photo-
sensitive agents and their effective rate of dispensings. While the
drug class ‘cardiovascular’ accounts for 15.2% of all photosensi-
tive drugs, their mean share of all dispensings per year in DE was
found to be 33.0%. A similar trend was evident for the drug class
‘metabolism’ as well as the class ‘anti-inflammatory’, while other
classes showed an inverse trend with a higher share among
photosensitive drugs vs. a lower dispensing rate (see Fig. S1a–g,
Supporting Information).
Development of an indicator for the photosensitizing
potential
A systematic MEDLINE search identified 1697 reports on pho-
tosensitivity linked to the 291 agents prescribed in DE and the
220 agents prescribed in AT, respectively, during the observa-
tional period. In the Table S1 (Supporting Information), all
Table 1 Continued
7 Others
Photosensitizers Verteporfin #+ Aminolevulinic acid #+ Dihaematoporhphyrin ether
Protoporphyrin Porfimer sodium # Trioxsalen
5-Methoxypsoralen + 8-Methoxypsoralen #+ Haematophyrin
Anthracene
Retinoids Isotretinoin #+ Acitretin #+ Etretinate
Tretinoin #+
Immunostimulants Aldesleukin #+
Immunosuppressants Tacrolimus #+ Omalizumab #+ Interferon beta #+
Azathioprine #+ Tocilizumab #+ Pirfenidone #+
Leflunomide #+
Phytotherapeutics Ginseng # Hydrastis canadensis # Angelica sinensis
Ruta #
Additives Cyclamate # Saccharin # Tartrazine #
Antidot Tiopronin # Acetylcysteine #+
Vitamins Pyridoxine #+
Vaccines Smallpox #
# indicates that the compound was dispensed and reimbursed in DE between 2010 and 2017; + indicates that the compound was reimbursed in Austria
between 2010 and 2017; and compounds printed in bold were reimbursed in both countries between 2010 and 2017.
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references are summarized and linked to the specific pharma-
ceutical agent. The highest number of drug-induced photosen-
sitivity reactions was reported for ‘anti-infectious’ drugs
(Fig. S2a, Supporting Information). In Fig. S2b (Supporting














































































































































































































































































































































































































































































































Figure 2 Total and relative number of drug dispensings in Germany (DE) and Austria (AT) between 2010 and 2017. Total amount of all
(a–d) and photosensitizing (e–f) drug dispensings. Relative amount of photosensitizing drug dispensings out of all dispensings (in %, g, h)
in DE and AT. Total amount of photosensitizing drug dispensings per 1000 insured persons in DE and AT (i, j).
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Correlation analysis of the dispensing rate with the
publication number
In order to determine the relevance of the absolute prescrip-
tion number, a correlation analysis with the aforementioned
indicator, the number of publications per drug according to
the systematic literature search, was performed. Plotting the
number of prescriptions vs. the number of reports on cuta-
neous photosensitivity reactions per agent identifies a small
number of drugs with the highest potential for causing pho-
tosensitivity in the real-life setting. For a further in-depth
analysis, these scatter plots were subdivided into four seg-
ments ‘X1’–‘X4’ (see Fig. 3a–h) as described in the Methods.
‘X1’ represents those drugs with the lowest number of dis-
pensings (<50 000 000 over the study period) and the lowest
number of reports on photosensitivity (<15 in DE and AT),
thus the group with the lowest significance for photosensi-
tive adverse events (Fig. 3a).
The segment ‘X2’ (Fig. 3b) comprises agents with a well-
documented photosensitizing potential (≥15 publications) but a
limited dispensing rate (<50 000 000 over the study period).
This category represents the prototypical drugs of well-known
photosensitizing potential such as vemurafenib, doxycycline or
amiodarone. The extracted segment ‘X2’ labelled with the
respective drug names is shown in Fig. 3b, and all agents are
summarized in Table 2.
Segment ‘X3’ (Fig. 3c) contains drugs with a well-documented
photosensitizing potential (≥15 publications) and high dispens-
ing rates (≥50 000 000 over the study period). In DE, only two
agents fall into this category, hydrochlorothiazide and ibuprofen.
In AT, none of the drugs falls into this segment; however, several
Figure 3 Combined analysis of drug dispensings and reference score. Scatterplot of the total number of dispensings of each single
agent plotted against the number of publications (‘reference score’) in Germany (DE) (a–d) and Austria (AT) (e–h). The resulting diagram in
(a) and (e) is subdivided into four segments each (‘X1’–‘X4’). In the subfigures b–d and f–h, a detailed analysis of ‘X2’–‘X4’ is shown.
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drugs are close to fit into this segment such as hydrochloroth-
iazide, furosemide, ciprofloxacin, naproxen and ibuprofen. These
two categories of drugs, namely diuretics and NSAIDs, are most
likely to cause photosensitivity reactions and are therefore most
important from a public health perspective (see Fig. 3c). In addi-
tion, prescription of several agents out of these drug groups is
increasing between 2010 and 2017 (data not shown).
The segment ‘X4’ (Fig. 3d) corresponds to drugs with a low
number of publications (<15) but a large number of annual dis-
pensings (≥50 000 000 over the study period). Given the limited
published evidence for causing photosensitivity, their role as
potential photosensitizers seems rather low. The data for the AT
study population are shown in Fig. 3e–h.
Discussion
Drug-induced photosensitivity reactions are rarely documented
in the published literature. This is partly due to underreporting
of affected subjects who might simply stop taking the causative
drug or attributing the ‘exaggerated sunburn’ to other causes,
such as excessive sun exposure. In addition, the lack of adequate
pharmacovigilance and a publication bias towards publishing
only extravagant cases may also play a role.
As a result, physicians without a particular interest in photo-
dermatology may only occasionally see and report cases of drug-
induced photosensitivity.10 Due to underreporting as well as the
diversity and abundance of drugs with photosensitizing poten-
tial, there are only rough approximations as to the actual inci-
dence of photosensitive reactions. In a report by Chaabane
et al.19 on patients presenting with drug-induced skin adverse
reactions, photosensitivity was the third commonest cause. In
specialized photodiagnostic units, systemic drug-induced photo-
sensitivity is reported to account for up to 15% of photoder-
matoses.20–25 However, these cases only represent those actually
referred for investigation of suspected photosensitivity and as
such do not reflect the true incidence.10
Up to the present, a large quantity of drugs has been associ-
ated with photosensitivity and this number is increasing con-
stantly.8 As part of our analysis, we have identified 387 drugs
with photosensitivity reported in the literature or in drug data-
bases. To our knowledge, this is the largest compilation of
potentially photosensitive drugs published so far. Of note, only
75.2% out of these agents were effectively prescribed in DE and
56.9% in AT, respectively. These data also suggest that, even if
there are some disparities between nations, a large part of phar-
maceuticals available for prescription might be comparable
among European countries.
When further analysing the dispensed drugs, it becomes evi-
dent that only a minority of all dispensed agents have a photo-
sensitizing potential. However, when looking at the percentage
of photosensitizers of all dispensed drugs, a completely different
picture evolves. Out of all drug dispensings, the mean cumula-
tive proportion of photosensitive drugs was 49.5% in DE and
48.2% in AT, respectively. These data indicate that although the
number of photosensitizers accounts for only a small portion of
all drugs available, almost half of all drug dispensings contained
a potentially photosensitive pharmaceutical agent. The impor-
tance of photosensitizing drugs is further underlined by the fact
that the number of their dispensings was increasing during the
study period, even if a plateau phase (or even decrease) was
observed over the more recent years.
Assuming that the incidence of photosensitive adverse reac-
tions is determined by the frequency of its use and its photosensi-
tizing potential a correlation of these two parameters was
performed. The resulting scatter plot was subdivided into four
segments revealing two segments that contain compounds with a
higher probability for causing cutaneous photosensitivity reac-
tions. The segment ‘X2’ contains drugs with a low number of pre-
scriptions but a high photosensitizing potential, such as
vemurafenib, or amiodarone. Given their rather narrow indica-
tions with limited total prescriptions in combination with their
well-known photosensitizing potential, the number of cases of
photosensitivity due to these drugs is expected to be rather low.
The segment ‘X3’ represents the segment with both a well-docu-
mented photosensitizing potential and a high prescription rate. In
DE, only two agents fall into this category, hydrochlorothiazide
and ibuprofen. In AT, none of the drugs falls into this category
but several drugs are close to it including hydrochlorothiazide,
furosemide, ciprofloxacin, naproxen and ibuprofen. Generally,
compounds in the ‘X3’ segment represent those drugs being most
important from a public health perspective as they will account
for most (and potentially undiagnosed) cases of photosensitivity.
The category ‘X3’ becomes even more important when consid-
ering the potential long-term effects of photosensitizing drugs.
Besides acute cutaneous adverse effects, an increasing number of
reports also suggest chronic sequelae such as increased photoag-
ing or photocarcinogenesis.26 While there is overwhelming evi-
dence for the photocarcinogenic effects of psoralens,25–32 several
Table 2 All photosensitizing agents (n = 26) in segment ‘X2’ of
Fig. 3 with the number of reports on photosensitivity in brackets,
used as indicator of the photosensitizing potential
Furosemide (22) Amiodarone (48)
Naproxen (24) Vandetanib (15)
Ketoprofen (43) Lomefloxacin (41)
Tiaprofenic acid (16) Enoxacin (20)
Piroxicam (48) Ciprofloxacin (32)
Methotrexate (18) Tetracycline (30)
Vemurafenib (68) Demeclocycline (33)
Dabrafenib (21) Doxycycline (50)
Griseofulvin (32) Quinine (27)
Voriconazole (38) Hypericin (18)
Promethazine (26) Cevimeline (40)
Fenofibrate (23) 8-Methoxypsoralen (31)
Porfimer (59) Pirfenidone (23)
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other phototoxic drugs have been associated with photocarcino-
genesis.33–38 This includes fluoroquinolones36,38–42 such as cipro-
floxacin or lomefloxacin, NSAIDs,36 thiazide diuretics,34,35,37,43
amiloride,34 amiodarone,44–47 tetracyclines,34 azathioprine,48–51
vemurafenib 52–54 or voriconazole.55 In general, these drugs may
increase the risk for spinocellular carcinoma and melanoma
although there are also reports on an increased risk for basal cell
carcinoma with amiodarone, ciprofloxacin or tetracycline.34,43–46
However, this aspect remains to be fully elucidated as some drugs
such as NSAIDs that may induce photosensitivity can even pre-
vent photocarcinogenesis.56 Moreover, epidemiological data do
not unequivocally support the association between drug-induced
photosensitivity and an elevated risk of skin cancer; instead, there
are also data on reduced risk.33 The complexity of this topic is
further exemplified by the different mechanisms involved in
drug-induced photosensitivity. Besides the classical mechanism
via exogenous chromophores and absorption, some drugs induce
photosensitivity by affecting DNA repair (e.g. in case of PARP
inhibitors57), by interacting with a signalling pathway (e.g. in case
of protein kinase inhibitors58) or by DNA adducts and interstrand
cross-linking (e.g. in case of psoralens5,59). These diverse mecha-
nisms of photosensitivity do not only complicate our understand-
ing, they also explain why drug-induced photosensitivity does not
automatically correlate with photocarcinogenicity. However, the
issue of drug-induced photocarcinogenicity was beyond the scope
of the current investigation.
A main limitation of the present study is the fact that it did
not include over-the-counter drugs and drugs dispensed to
patients without public insurance coverage. In addition, drugs
with a price below the copayment rate were also not factored in
the analysis since their dispensing is not registered by the statu-
tory health insurances. In the end, it would be desirable to deter-
mine the actual number of individuals which were exposed to
the photosensitive risk. However, from an epidemiological point
of view, an extrapolation from the number of dispensed photo-
sensitive drugs to the number of individuals affected is not pos-
sible. From the available data set, it is not possible to determine
how many packages of the individual drugs were prescribed for
how many patients and whether these medications were actually
taken by these individuals (and for how long). These questions
could only be clarified satisfactorily within the context of a
prospective patient-centred study. In addition, the ‘indicator’ of
the photosensitizing potential of a drug as established in our
study only reflects current published knowledge on drug-
induced photosensitivity. Unpublished cases or cases not pub-
lished in MEDLINE or in Litt’s Drug Eruption & Reaction Data-
base were not captured by the current analysis.
In summary, our findings indicate that photosensitive drugs
represent about half of all dispensings of reimbursed drugs in
DE and AT. Besides the potential of causing acute cutaneous
photosensitivity reactions, the recent reports on the association
of phototoxic drugs with photocarcinogenesis cause particular
concern. In the latter regard, special attention should be given to
drugs with high dispensing numbers and a high phototoxic
potential, such as hydrochlorothiazide.
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